Ono Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4528) has disclosed results from five Phase 2 clinical studies of ONO-1110, an investigational oral endocannabinoid modulator, reporting that three trials in chronic pain conditions failed to meet their primary endpoints while selected secondary analyses suggested possible therapeutic activity. Announced on October 29, 2026 in Japan, the results cover postherpetic neuralgia, fibromyalgia, Hunner-type interstitial cystitis, major depressive disorder and social anxiety disorder.
The disclosure represents an important decision point for the Japanese pharmaceutical manufacturer because the clinical programme has generated different findings across its five investigated indications. Ono Pharmaceutical plans further studies in the three pain-related conditions despite the unsuccessful primary endpoint results, while discontinuing further clinical development for major depressive disorder and social anxiety disorder because no efficacy signals were identified.
The distinction between an unsuccessful primary endpoint and a potentially useful exploratory finding is central to interpreting the announcement. ONO-1110 has not established efficacy in any of the five Phase 2 programmes, and the company has not released the detailed numerical results required to evaluate the magnitude and consistency of the reported pain signals. Future development will depend on whether those observations can be translated into prospectively defined, statistically persuasive clinical outcomes.
Why did Ono Pharmaceutical decide to continue ONO-1110 development after three Phase 2 pain studies missed their primary endpoints?
The three studies that generated potential efficacy signals were ONO-1110-04 in postherpetic neuralgia, ONO-1110-05 in fibromyalgia and ONO-1110-06 in Hunner-type interstitial cystitis. Each was designed as a randomised, placebo-controlled Phase 2 investigation evaluating the efficacy and safety of oral ONO-1110. None achieved its primary efficacy endpoint, meaning that the studies did not demonstrate their intended primary treatment effects under the prespecified analysis framework.
Ono Pharmaceutical nevertheless reported improvements in numerical rating scale pain assessments in certain patient subgroups. The company described these findings as arising from prespecified subgroup analyses and exploratory post hoc analyses. Such observations can provide useful information for future trial design, particularly when treatment response may depend on patient characteristics or disease mechanisms.
However, subgroup findings require more cautious interpretation than successful primary endpoints. When investigators examine multiple patient characteristics or outcome measures, apparently favourable results can occur by chance. Post hoc analyses carry additional uncertainty because they are developed after investigators have access to the study data.
The company has not disclosed which specific subgroups produced the strongest signals or how the findings were distributed across the three trials. Detailed effect sizes, confidence intervals, statistical significance measures and responder rates remain unavailable. Consequently, the announcement supports further investigation but does not establish that ONO-1110 provides clinically meaningful pain relief.
For Ono Pharmaceutical, continuing development appears to reflect a decision that the exploratory findings retain sufficient scientific interest to justify additional research. The critical next step will be identifying whether a reproducible treatment effect exists in a clearly defined patient population. Without that evidence, the promising subgroup observations could prove difficult to translate into an approvable medicine.
How does ONO-1110 target the endocannabinoid system, and why could that mechanism be relevant to chronic pain?
The endocannabinoid system participates in the regulation of several physiological processes, including pain transmission, emotional responses and neuronal signalling. It involves naturally occurring signalling molecules and receptors that help modulate communication between cells. Researchers have investigated this system as a potential therapeutic target for conditions involving persistent pain and altered nervous system activity.
ONO-1110 is an orally available endocannabinoid modulator developed by Ono Pharmaceutical. According to the company, the investigational medicine is designed to influence endogenous signalling processes associated with neuronal activity and pain transmission. The approach aims to modify the body’s own regulatory mechanisms rather than simply reproduce the effects of administering an external cannabinoid.
The precise molecular target and detailed pharmacological mechanism of ONO-1110 have not been comprehensively disclosed in the October announcement. It would therefore be inappropriate to describe the medicine as a specific cannabinoid receptor agonist, antagonist or enzyme inhibitor without additional verified information. The company has identified the broader endocannabinoid pathway as the relevant biological rationale.
Modulating endogenous pain-related signalling could theoretically influence different forms of persistent pain. However, postherpetic neuralgia, fibromyalgia and bladder pain syndrome involve distinct combinations of peripheral nerve activity, central processing and local tissue pathology. A shared biological pathway does not guarantee similar treatment responses across these conditions.
The Phase 2 results illustrate the difficulty of translating mechanistic plausibility into reliable clinical effects. Although the company observed possible pain improvements in selected analyses, the primary endpoints were not met. Further studies will need to determine whether the mechanism can produce consistent benefits under appropriately controlled conditions.
What did the ONO-1110-04 study investigate in patients with postherpetic neuralgia?
Postherpetic neuralgia is a neuropathic pain condition that can develop after herpes zoster infection, commonly known as shingles. The disorder results from nerve injury associated with varicella-zoster virus reactivation and can produce persistent burning, stabbing or electric shock-like pain. Some patients also experience allodynia, where normally harmless contact causes pain.
The ONO-1110-04 study was conducted in Japan as a multicentre, randomised, double-blind, placebo-controlled Phase 2 investigation. Its planned enrolment was approximately 140 patients, and participants received oral ONO-1110 or placebo once daily for eight weeks. The trial evaluated efficacy, safety, tolerability and pharmacokinetics.
The company’s announcement confirms that the study did not meet its primary endpoint. However, certain analyses suggested improvement in pain measured through the numerical rating scale. The numerical rating scale is commonly used in clinical pain studies because it allows patients to report pain intensity using a standardised measurement.
The clinical relevance of any observed improvement depends on the size of the difference compared with placebo and whether the change exceeds a meaningful threshold for patients. A numerical reduction may not necessarily translate into improved sleep, daily functioning or quality of life. The announcement does not provide enough information to assess those relationships.
Existing postherpetic neuralgia treatments include medicines directed at neuropathic pain, but patients may experience inadequate relief or adverse effects. This creates a rationale for investigating new mechanisms of action. Nevertheless, ONO-1110 must demonstrate convincing benefits in future studies before it can be considered a meaningful addition to the treatment landscape.
Why are the ONO-1110-05 fibromyalgia findings difficult to interpret without detailed subgroup data?
Fibromyalgia is a chronic disorder characterised by widespread pain, fatigue, sleep disturbances and other symptoms that can substantially affect daily functioning. Its pathophysiology involves complex changes in pain processing and nervous system regulation. These characteristics make treatment development challenging because patients vary considerably in symptom patterns and responses.
The ONO-1110-05 study was designed as a multicentre, randomised, double-blind, placebo-controlled Phase 2 trial in Japan. The planned sample size was 160 patients, with participants receiving ONO-1110 or placebo once daily for eight weeks. Its registered primary efficacy assessment concerned change in the weekly mean average pain score.
Ono Pharmaceutical confirmed that the study did not meet its primary endpoint. The company nevertheless identified possible improvements in pain in selected analyses, without disclosing which patient characteristics were associated with those findings. This creates uncertainty over whether the observed signal reflects a genuine treatment-responsive subgroup or random variation.
Subgroup analysis can be particularly challenging in fibromyalgia because symptoms are influenced by multiple biological and psychological factors. A treatment effect observed among a small subset of patients may not generalise to individuals with different symptom severity, comorbidities or baseline pain patterns. Without adequate statistical detail, the strength of the reported signal cannot be evaluated.
Future studies would need to specify the intended population and primary outcome before treatment begins. Investigators should also examine whether improvements in pain are accompanied by meaningful changes in function, sleep or overall symptom burden. Such evidence would be more persuasive than isolated exploratory pain-score differences.
Could Hunner-type interstitial cystitis provide a more specific development opportunity for ONO-1110?
Hunner-type interstitial cystitis is a form of bladder pain syndrome associated with characteristic inflammatory lesions visible during cystoscopic examination. Patients may experience chronic bladder pain, urinary urgency, increased urinary frequency and substantial disruption to daily activities. The condition differs from other bladder pain presentations in its identifiable lesion-related characteristics.
The ONO-1110-06 Phase 2 study evaluated oral treatment in patients with Hunner-type interstitial cystitis. The multicentre, randomised, placebo-controlled trial was conducted in Japan, with a planned sample size of approximately 50 patients and a 12-week treatment period. The study assessed efficacy, safety, tolerability and pharmacokinetics.
Like the other pain studies, ONO-1110-06 failed to achieve its primary endpoint. Ono Pharmaceutical nevertheless reported possible pain improvement in selected subgroup or exploratory analyses. The company has not disclosed whether the observations were associated with baseline symptom severity, lesion characteristics or another factor.
The existence of a recognisable disease subtype could potentially help investigators define eligibility for further research. However, a more specific diagnosis does not automatically make a medicine more likely to succeed. Researchers still need to establish whether the proposed biological mechanism affects the disease processes responsible for pain.
Another important consideration is the role of treatments directed at the bladder lesions themselves. Pain reduction may be influenced by local disease activity, other interventions and broader neurological mechanisms. Future studies will need to account for these factors when evaluating whether ONO-1110 provides additional therapeutic benefit.
Why has Ono Pharmaceutical discontinued ONO-1110 development for major depression and social anxiety disorder?
The two remaining Phase 2 studies investigated whether ONO-1110 could influence psychiatric symptoms associated with major depressive disorder and social anxiety disorder. Both conditions involve complex neural processes, making the endocannabinoid system a biologically interesting research target. However, plausible effects on neuronal signalling do not establish that a particular medicine will improve psychiatric outcomes.
The ONO-1110-07 study evaluated the investigational treatment in major depressive disorder, while ONO-1110-08 investigated social anxiety disorder. Both were registered as randomised, double-blind, placebo-controlled Phase 2 studies conducted in Japan. Their planned sample sizes were approximately 100 participants each.
Ono Pharmaceutical reported that neither programme generated efficacy signals supporting further development. Consequently, the company does not plan additional clinical trials of ONO-1110 for these indications. This represents a clearer discontinuation decision than the situation in the three pain studies, where exploratory findings have prompted continued investigation.
The announcement does not disclose detailed psychiatric outcome scores or the numerical differences between treatment groups. It therefore does not permit independent assessment of how closely the results approached their efficacy thresholds. Nevertheless, the company’s stated development decision establishes that the available evidence was insufficient to support continuation in either indication.
The decision also narrows the strategic scope of ONO-1110. Rather than maintaining simultaneous programmes across pain and psychiatric disorders, Ono Pharmaceutical intends to focus future resources on conditions where some evidence of possible activity was observed. Whether this prioritisation ultimately improves the candidate’s development prospects remains uncertain.
How should clinicians and researchers interpret Ono Pharmaceutical’s reported safety findings across five Phase 2 studies?
Ono Pharmaceutical described ONO-1110 as demonstrating a favourable safety profile across the five Phase 2 investigations. This is potentially encouraging because chronic pain treatments may require repeated or prolonged administration. However, the company has not disclosed detailed adverse-event rates, discontinuation figures or serious adverse-event findings in the October announcement.
A broad statement about tolerability is not sufficient to determine the clinical safety profile of an investigational medicine. Different adverse events may have different implications depending on the intended patient population and treatment duration. Safety findings must also be considered in relation to the magnitude of any demonstrated clinical benefit.
The eight-week treatment periods in postherpetic neuralgia and fibromyalgia provide information about relatively short-term exposure. The 12-week Hunner-type interstitial cystitis study offers a somewhat longer observation period, but none of these designs establishes long-term tolerability. Chronic conditions may require treatment extending substantially beyond the initial Phase 2 assessment.
Future studies will need to examine adverse events, discontinuations, laboratory findings and other relevant safety measures in greater detail. Any effects on cognition, mood or other central nervous system functions would require appropriate evaluation given the drug’s intended biological pathway. Such monitoring should be based on observed findings and pharmacology rather than assumptions about a cannabinoid-related mechanism.
A favourable safety profile could become commercially important if ONO-1110 ultimately demonstrates meaningful analgesic efficacy. However, tolerability cannot compensate for the absence of a reproducible treatment effect. Regulatory development will require evidence that the benefits outweigh the risks in the intended population.
What trial design changes could help Ono Pharmaceutical determine whether the pain signals are reproducible?
The central challenge for future ONO-1110 development is converting exploratory observations into prospectively testable hypotheses. Ono Pharmaceutical will need to examine the full Phase 2 datasets to determine whether any patient characteristics consistently predict response. Findings identified only after examining treatment results should be evaluated in new studies rather than treated as established predictors.
Patient selection could become an important consideration. The three pain disorders differ in pathophysiology, symptom measurement and available treatment options, meaning that a single development strategy may not be appropriate across all indications. The company may need to prioritise the condition with the strongest biological and statistical rationale.
Endpoint selection will also be critical. Pain intensity scores are commonly used in clinical studies, but their interpretation depends on the chosen assessment period, baseline severity and magnitude of improvement. Future protocols should define clinically meaningful differences and establish how missing data and treatment discontinuations will be handled.
Dose selection represents another unresolved question. The October announcement does not identify whether the three pain studies demonstrated a consistent exposure-response relationship or whether particular doses produced more favourable outcomes. Pharmacokinetic findings could help determine whether inadequate exposure contributed to the unsuccessful primary results.
Finally, the statistical analysis plan will need to account for multiple comparisons and subgroup assessments. A future trial designed around a selected subgroup may provide stronger evidence than repeating broad exploratory analyses. However, such a strategy must be supported by adequate patient numbers and a scientifically credible eligibility framework.
What do the mixed ONO-1110 results mean for Ono Pharmaceutical’s pipeline and investor sentiment?
Ono Pharmaceutical is a publicly traded Japanese pharmaceutical manufacturer with activities spanning oncology, immunology, inflammation and neurology. Its portfolio includes established commercial medicines and investigational programmes developed internally and through partnerships. ONO-1110 therefore represents one component of a broader pharmaceutical business rather than its sole development asset.
The Phase 2 disclosure is best understood as a mixed clinical development setback. Three pain studies missed their primary endpoints, while the psychiatric programmes will not advance further. The exploratory pain findings preserve a potential development opportunity, but they do not reverse the unsuccessful primary outcomes.
For investors, the most important uncertainty concerns the additional clinical investment required to establish whether ONO-1110 has a viable therapeutic role. Further studies will create development costs and may require changes in trial design, patient selection or dosing strategy. The absence of detailed numerical efficacy results also limits the ability to assess the probability of future success.
Ono Pharmaceutical’s shares closed at ¥2,471.5 on October 28, according to Tokyo market data, representing a 0.43% increase from the preceding session. That trading session occurred before the Japan-dated results announcement, so the movement should not be interpreted as a reaction to the clinical findings. Subsequent market assessments will depend on how investors evaluate the failed endpoints and the cost of continued development.
The broader commercial question is whether the company can identify one or more pain populations in which ONO-1110 demonstrates a clinically meaningful advantage. Until additional evidence becomes available, assigning substantial future revenue to the programme would be premature. The most relevant milestone will be a clearly defined subsequent trial that prospectively tests the reported pain signal.
Ono Pharmaceutical has chosen to preserve the pain-development programme while ending two psychiatric investigations. That decision provides a more focused clinical direction but does not establish that ONO-1110 is effective in any indication. The next stage will determine whether the exploratory observations represent a reproducible treatment effect or whether the compound’s development prospects remain limited by the unsuccessful Phase 2 results.
